Tactile Systems Technology, Inc., operating as Tactile Medical, is a medical technology company that develops and provides at-home medical devices for the treatment of chronic diseases, primarily vascular disorders and respiratory conditions. The company focuses on therapeutic areas including lymphedema, chronic venous insufficiency, lipedema, and airway clearance for chronic respiratory conditions such as bronchiectasis. Its core product portfolio consists of pneumatic compression systems, including the Flexitouch Plus, Entre Plus, and Nimbl platforms, which are sold or rented to patients for managing swelling and related symptoms. Additionally, the company offers the AffloVest, a portable, battery-powered wearable vest for airway clearance therapy. Tactile Medical employs a direct-to-patient and provider model for its lymphedema products, managing insurance claims and providing training, while its respiratory products are distributed through durable medical equipment providers. The company serves patients in the United States, with coverage from private payers, Medicare, the Veterans Administration, and certain Medicaid programs. Founded in 1995, the company began doing business as Tactile Medical in 2013.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage tactilemedical.com
Sector Healthcare IR page investors.tactilemedical.com
Tags
pneumatic compression, lymphedema treatment, chronic venous insufficiency, airway clearance, home healthcare, respiratory therapy, durable medical equipment, vascular disease, oncology support, patient education, Flexitouch Plus, Entre Plus, Nimbl, AffloVest, Flexitouch, Entre, ComfortEase, Kylee, Healing Right at Home
Press page investors.tactilemedical.com/news

Metrics

Valuation  
Market cap $ 607.39M
Market cap (USD) $ 607.39M
P/E 26.47
PEG —
P/BV 2.67
P/S 1.70
P/OCF 18.87
P/FCF 20.93
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.8%
ROI 12.9%
ROIC 12.0%
Profit margin 5.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 329.522M 292.984M 274.423M 246.785M 208.057M 187.13M 189.492M 143.751M 109.283M 84.542M 62.872M
Net profit 19.086M 16.96M 28.515M -17.866M -11.811M -620K 10.971M 6.623M 5.855M 2.879M 1.393M
Free cash flow 40.431M 38.263M 33.531M 3.429M 528K 735K -2.936M 4.811M 446K 6.258M 1.807M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 29 17.13 14.3 11.48 19.03 44.94 67.51 45.55 28.98 16.41 —
Price performance 12m 0.69 0.2 0.25 -0.4 -0.58 -0.33 0.48 0.57 0.77 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 15M 17.6M 24.3M 33.4M 43.8M 49.5M 54.8M 43.2M 44.9M 43.9M
↳ YoY growth +6.0% +17.5% +38.1% +37.4% +31.1% +12.8% +10.8% -21.3% +4.1% -2.4%
↳ 5y CAGR +25.4% +27.0% +25.5% +12.2% +6.1% +0.0%
Lease liabilities (USD) — — — 16.6M 21.4M 25.9M 23.4M 21.2M 18.9M 16M
Cash and deposits (USD) 30.7M 24M 20.1M 22.8M 47.9M 28.2M 21.9M 61M 94.4M 83.4M
Intangible assets (USD) — 2.22M 5.34M 5.31M 1.68M 54.1M 50.4M 46.7M 42.8M 39.2M
Right-of-use assets (USD) — — — 15.9M 20.1M 24M 21.3M 19.1M 16.6M 13.8M
Cash flow detail
Operating cash flow (USD) 7.03M 4.19M 9.01M 2.51M 2.79M 2.63M 5.21M 35.9M 40.7M 42.8M
Purchases of property, plant and equipment (USD) -775,000 -3.75M -4.2M -5.45M -2.06M -2.1M -1.78M -2.32M -2.39M -2.38M
Purchases of intangible assets (USD) -58,000 -74,000 -5.35M -542,000 -232,000 -252,000 -140,000 -157,000 -117,000 -155,000
Change in receivables (cash effect) (USD) -1.42M -3.69M -6.71M -9.11M -10.4M -5.63M -5.35M 11.7M -1.76M 1.06M
Change in inventories (cash effect) (USD) -773,000 -4.49M -870,000 -7.87M 318,000 972,000 -3.91M 597,000 3.86M 4.64M
Change in payables (cash effect) (USD) 1.74M 462,000 690,000 -1.39M 337,000 826,000 4.96M -3.85M -1.09M -758,000
Share buybacks (cash effect) (USD) — -493,000 — — — — — — -3.51M -26.6M
Interest paid (cash effect) (USD) — — -9,000 — — -130,000 -2.19M -4.56M -2.11M -1.22M
Income taxes paid (cash effect) (USD) -2.16M -923,000 -2.88M -344,000 -543,000 -1.59M -44,000 -5.82M -6.85M -2.5M
Share-based compensation (USD) 1.89M 4.24M 7.97M 9.82M 10.7M 10.2M 9.6M 7.55M 7.82M 8.36M
Operating cash flow before change in receivables (USD) 8.45M 7.88M 15.7M 11.6M 13.2M 8.26M 10.6M 24.2M 42.4M 41.8M
Free cash flow (OCF - PPE - intangibles) (USD) 6.2M 372,000 -539,000 -3.48M 503,000 276,000 3.29M 33.4M 38.1M 40.3M
Income detail
Research and development expense (USD) 4.48M 5.06M 5.29M 5.17M 5.26M 5.66M 7.09M 7.82M 8.83M 8.48M
↳ 5y CAGR +12.7% +4.1% +4.8% +7.0% +8.1% +11.3% +10.0%
Total comprehensive income (USD) 2.87M 5.82M 6.66M 11M -646,000 -11.8M -17.9M — — —
Comprehensive income to owners (USD) 2.87M 5.82M 6.66M 11M -646,000 -11.8M -17.9M — — —
Provision for credit losses (USD) 7.09M 6.49M — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 48.6% 39.8% — — — — — — — —
Reported Feb 27, 2017 Aug 6, 2018 Feb 28, 2019 Feb 26, 2020 Feb 23, 2021 Feb 23, 2022 Feb 21, 2023 Feb 20, 2024 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MINNEAPOLIS, MN, November 2, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Summary and Recent Business Highlights:

● Total revenue increased 7% year-over-year to $91.9 million; revenue from our lymphedema product line increased 13% year-over-year to $81.8 million

● Gross margin expanded to 77% from 76% in Q3 2025

● Net income decreased to $7.2 million from $8.2 million in Q3 2025

● Adjusted EBITDA was $14.3 million, compared to $14.4 million in Q3 2025

● Received FDA 510(k) clearance expanding the LymphaTech 3D Scanner’s indication to aid in the assessment of lymphedema

● Submitted a 510(k) application to the FDA for Flexitouch® Pro, featuring enhancements to the Company’s advanced pneumatic compression system

● Appointed Steve Kiewiet as Chief Operating Officer, with responsibility for order operations and patient services

● Repurchased $6.2 million of stock under the Company’s share repurchase program

“Our results underscore the strength and dur

October 19, 2026

PDF Version

MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2026 financial results will be released after the market closes on Monday, November 2, 2026.

Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 2, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13762880. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13762880. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries: Sam Bentzinger Gilmartin Group [email protected]

Primary Logo

August 10, 2026

PDF Version

MINNEAPOLIS, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Summary and Recent Business Highlights:

  • Total revenue increased 9% year-over-year to $85.7 million

  • Gross margin expanded to 76% from 75% in Q2 2025

  • Net income increased to $7.8 million from $3.2 million in Q2 2025

  • Adjusted EBITDA increased to $11.4 million from $7.7 million in Q2 2025

  • Entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve™ Wearable Compression Device to Veterans and active-duty service members and their dependents

  • Commercially launched the next-generation AffloVest Airway Clearance Therapy system

  • Repurchased $5.3 million of stock under the Company’s share repurchase program

  • Publication of six-month clinical results from the Company's randomized controlled trial evaluating Flexitouch® Plus for the treatment of head and neck cancer-related lymphedema

“We are encouraged by our strong momentum in the second quarter. We delivered solid revenue growth, expanded gross margin, and generated meaningful adjusted EBITDA, underscoring the strength of our business model and our team’s disciplined execution,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Our core lymphedema business remains healthy and our view of the long-term opportunity for AffloVest to be a leading high frequency chest wall oscillation technology therapy is unchanged despite the impact of a temporary inventory management dynamic related to the launch of our next-generation AffloVest system during the quarter.”

Ms. Dodd continued, “Operationally, we made tangible progress furthering our broader strategy. We advanced integration activities for LymphaTech, which expands our portfolio across the lymphedema care continuum, launched our next-generation AffloVest system, and secured exclusive Department of Veterans Affairs and Department of Defense distribution rights for MyoSleeve. These product and capability investments strengthen and broaden our patient reach and market expansion, enabling diagnostic and therapy options for patients and providers. With a clear growth and leverage strategy and a differentiated portfolio, we believe Tactile Medical is well-positioned for sustainable, profitable growth in the years ahead.”

Second Quarter 2026 Financial Results

Total revenue in the second quarter of 2026 increased $6.8 million, or 9%, to $85.7 million, compared to $78.9 million in the second quarter of 2025. The increase in total revenue was attributable to an increase of $7.7 million, or 12%, in sales and rentals of the lymphedema product line, partially offset by a decrease of $0.9 million, or 7%, in sales of the airway clearance product line, due to temporary inventory management dynamics associated with the launch of the Company’s next-generation AffloVest system among a few large DME providers during the quarter.

Gross profit in the second quarter of 2026 increased $6.6 million, or 11%, to $65.3 million, compared to $58.8 million in the second quarter of 2025. Gross margin was 76% of revenue, compared to 75% of revenue in the second quarter of 2025. Gross margin improvement reflected continued operating execution and product cost discipline.

Operating expenses in the second quarter of 2026 increased $3.8 million, or 7%, to $58.5 million, compared to $54.7 million in the second quarter of 2025. The increase primarily reflected continued investments to support long-term growth initiatives.

Operating income was $6.8 million in the second quarter of 2026, compared to $4.1 million in the second quarter of 2025.

Income tax benefit was $0.4 million in the second quarter of 2026, compared to an income tax expense of $1.3 million in the second quarter of 2025.

Net income in the second quarter of 2026 was $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per diluted share, in the second quarter of 2025.

Weighted average shares used to compute diluted net income per share were 23.1 million and 23.2 million for the second quarters of 2026 and 2025, respectively.

Adjusted EBITDA was $11.4 million in the second quarter of 2026, compared to $7.7 million in the second quarter of 2025, reflecting revenue growth, gross margin expansion and disciplined expense management.

First Six Months 2026 Financial Results

Total revenue for the six months ended June 30, 2026, increased $20.8 million, or 15%, to $161.0 million, compared to $140.2 million for the six months ended June 30, 2025. The increase in total revenue was attributable to an increase of $19.3 million, or 17%, in sales and rentals of the lymphedema product line and an increase of $1.5 million, or 6%, in sales of the airway clearance product line for the six months ended June 30, 2026, compared to the six months ended June 30, 2025.

Net income for the six months ended June 30, 2026, was $6.0 million, or $0.26 per diluted share, compared to $0.2 million, or $0.01 per diluted share, for the six months ended June 30, 2025.

Weighted average shares used to compute diluted net income per share were 23.1 million and 23.7 million for the six months ended June 30, 2026 and 2025, respectively.

Adjusted EBITDA was $15.1 million in the six months ended June 30, 2026, compared to $7.4 million in the six months ended June 30, 2025.

Balance Sheet Summary

As of June 30, 2026, the Company had $69.9 million in cash and no outstanding borrowings under its credit agreement, compared to $83.4 million in cash and no outstanding borrowings under its credit agreement as of December 31, 2025. The Company repurchased $5.3 million of its stock during the second quarter under its repurchase program. As of June 30, 2026, $18.7 million remained available under the Company’s $25.0 million share repurchase program, which expires November 3, 2027.

2026 Financial Outlook

The Company is updating its 2026 financial outlook and now expects full year 2026 total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year.

The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million, compared to adjusted EBITDA of $44.8 million in 2025.

The revised revenue outlook reflects continued confidence in the Company's lymphedema product line, partially offset by a more conservative view of airway clearance product line ordering patterns as certain DME providers work through near-term elevated inventory levels related to the launch of the Company’s next-generation AffloVest system.

Conference Call

Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on August 10, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13761142. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13761142. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements, including guidance for the full year 2026. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions, including inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, the Company’s products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net income, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related costs, plus executive transition costs, and plus acquisition and integration costs. Reconciliation of this non-GAAP financial measure to its most directly comparable GAAP measure is included in this press release.

This non-GAAP financial measure is presented because the Company believes it is a useful indicator of its operating performance. Management uses this measure principally as a measure of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes this measure is useful to investors as supplemental information and because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes this non-GAAP financial measure is useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.

The non-GAAP financial measure presented in this release should not be considered as an alternative to, or superior to, its respective GAAP financial measure, as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

Investor Inquiries:

Sam Bentzinger Gilmartin Group [email protected]

| | | | | | | |

| Tactile Systems Technology, Inc. |

| Condensed Consolidated Balance Sheets |

| (Unaudited) |

| | | June 30, | | December 31, |

| (In thousands, except share and per share data) | | 2026 | | 2025 |

| Assets | | | | | |

| Current assets | | | | | | |

| Cash | | $ | 69,853 | | $ | 83,446 |

| Accounts receivable, net | | | 43,140 | | | 43,876 |

| Net investment in leases | | | 14,927 | | | 15,754 |

| Inventories | | | 16,845 | | | 14,025 |

| Income taxes receivable | | | 912 | | | — |

| Prepaid expenses and other current assets | | | 11,925 | | | 8,066 |

| Total current assets | | | 157,602 | | | 165,167 |

| Non-current assets | | | | | | |

| Property and equipment, net | | | 5,849 | | | 5,117 |

| Right of use operating lease assets | | | 12,553 | | | 13,798 |

| Intangible assets, net | | | 44,747 | | | 39,167 |

| Goodwill | | | 39,554 | | | 31,063 |

| Deferred income taxes | | | 8,703 | | | 9,783 |

| Other non-current assets | | | 10,660 | | | 9,847 |

| Total non-current assets | | | 122,066 | | | 108,775 |

| Total assets | | $ | 279,668 | | $ | 273,942 |

| Liabilities and Stockholders' Equity | | | | | | |

| Current liabilities | | | | | | |

| Accounts payable | | $ | 7,923 | | $ | 4,968 |

| Accrued payroll and related taxes | | | 15,615 | | | 19,378 |

| Accrued expenses | | | 8,423 | | | 8,531 |

| Income taxes payable | | | — | | | 1,428 |

| Operating lease liabilities | | | 3,095 | | | 3,195 |

| Other current liabilities | | | 3,197 | | | 3,457 |

| Total current liabilities | | | 38,253 | | | 40,957 |

| Non-current liabilities | | | | | | |

| Accrued warranty reserve, non-current | | | 1,079 | | | 1,045 |

| Income taxes payable, non-current | | | 370 | | | 275 |

| Operating lease liabilities, non-current | | | 11,267 | | | 12,763 |

| Other non-current liabilities | | | 4,863 | | | — |

| Total non-current liabilities | | | 17,579 | | | 14,083 |

| Total liabilities | | | 55,832 | | | 55,040 |

| Stockholders’ equity: | | | | | | |

| Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2026 and December 31, 2025 | | | — | | | — |

| Common stock, $0.001 par value, 300,000,000 shares authorized; 22,701,241 shares issued and outstanding as of June 30, 2026; 22,438,926 shares issued and outstanding as of December 31, 2025 | | | 23 | | | 22 |

| Additional paid-in capital | | | 162,851 | | | 163,940 |

| Retained earnings | | | 60,962 | | | 54,940 |

| Total stockholders’ equity | | | 223,836 | | | 218,902 |

| Total liabilities and stockholders’ equity | | $ | 279,668 | | $ | 273,942 |

| | | | | | | | | | | | | |

| Tactile Systems Technology, Inc. |

| Condensed Consolidated Statements of Operations |

| (Unaudited) |

| | | | | | | | | | | | | |

| | | | | | | | | | | | | |

| | | Three Months Ended | | Six Months Ended |

| | | June 30, | | June 30, |

| (In thousands, except share and per share data) | | 2026 | | 2025 | | 2026 | | 2025 |

| Revenue | | | | | | | | | | | | |

| Sales revenue | | $ | 76,489 | | | $ | 70,531 | | | $ | 143,455 | | | $ | 123,000 | |

| Rental revenue | | | 9,209 | | | | 8,374 | | | | 17,510 | | | | 17,173 | |

| Total revenue | | | 85,698 | | | | 78,905 | | | | 160,965 | | | | 140,173 | |

| Cost of revenue | | | | | | | | | | | | |

| Cost of sales revenue | | | 17,628 | | | | 17,483 | | | | 32,887 | | | | 31,374 | |

| Cost of rental revenue | | | 2,721 | | | | 2,629 | | | | 5,115 | | | | 4,660 | |

| Total cost of revenue | | | 20,349 | | | | 20,112 | | | | 38,002 | | | | 36,034 | |

| Gross profit | | | | | | | | | | | | |

| Gross profit - sales revenue | | | 58,861 | | | | 53,048 | | | | 110,568 | | | | 91,626 | |

| Gross profit - rental revenue | | | 6,488 | | | | 5,745 | | | | 12,395 | | | | 12,513 | |

| Gross profit | | | 65,349 | | | | 58,793 | | | | 122,963 | | | | 104,139 | |

| Operating expenses | | | | | | | | | | | | |

| Sales and marketing | | | 32,012 | | | | 30,039 | | | | 64,744 | | | | 57,555 | |

| Research and development | | | 2,501 | | | | 2,018 | | | | 5,277 | | | | 3,759 | |

| Reimbursement, general and administrative | | | 23,360 | | | | 22,034 | | | | 46,404 | | | | 42,032 | |

| Intangible asset amortization and earn-out | | | 650 | | | | 619 | | | | 1,246 | | | | 1,252 | |

| Total operating expenses | | | 58,523 | | | | 54,710 | | | | 117,671 | | | | 104,598 | |

| Income (loss) from operations | | | 6,826 | | | | 4,083 | | | | 5,292 | | | | (459 | ) |

| Interest income | | | 561 | | | | 850 | | | | 1,227 | | | | 1,745 | |

| Interest expense | | | (19 | ) | | | (410 | ) | | | (47 | ) | | | (834 | ) |

| Other income | | | — | | | | 1 | | | | — | | | | 1 | |

| Income before income taxes | | | 7,368 | | | | 4,524 | | | | 6,472 | | | | 453 | |

| Income tax (benefit) expense | | | (417 | ) | | | 1,307 | | | | 450 | | | | 210 | |

| Net income | | $ | 7,785 | | | $ | 3,217 | | | $ | 6,022 | | | $ | 243 | |

| Net income per common share | | | | | | | | | | | | |

| Basic | | $ | 0.34 | | | $ | 0.14 | | | $ | 0.27 | | | $ | 0.01 | |

| Diluted | | $ | 0.34 | | | $ | 0.14 | | | $ | 0.26 | | | $ | 0.01 | |

| Weighted-average common shares used to compute net income per common share | | | | | | | | | | | | |

| Basic | | | 22,676,673 | | | | 23,092,469 | | | | 22,620,546 | | | | 23,399,848 | |

| Diluted | | | 23,058,902 | | | | 23,237,671 | | | | 23,135,040 | | | | 23,679,220 | |

| | | | | | | |

| Tactile Systems Technology, Inc. |

| Condensed Consolidated Statements of Cash Flows |

| (Unaudited) |

| | | |

| | | Six Months Ended June 30, |

| (In thousands) | | 2026 | | 2025 |

| Cash flows from operating activities | | | | | | |

| Net income | | $ | 6,022 | | | $ | 243 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | | | | |

| Depreciation and amortization | | | 3,450 | | | | 3,385 | |

| Deferred income taxes | | | 42 | | | | (22 | ) |

| Stock-based compensation expense | | | 4,040 | | | | 4,005 | |

| Loss on disposal of property and equipment and intangibles | | | 73 | | | | 68 | |

| Changes in assets and liabilities, net of acquisition: | | | | | | |

| Accounts receivable, net | | | 755 | | | | 11,851 | |

| Net investment in leases | | | 827 | | | | 83 | |

| Inventories | | | (2,820 | ) | | | 1,555 | |

| Income taxes payable | | | (2,245 | ) | | | (611 | ) |

| Prepaid expenses and other assets | | | (5,174 | ) | | | (4,735 | ) |

| Right of use operating lease assets | | | (351 | ) | | | (289 | ) |

| Accounts payable | | | 2,886 | | | | 2,319 | |

| Accrued payroll and related taxes | | | (3,763 | ) | | | (5,245 | ) |

| Accrued expenses and other liabilities | | | (827 | ) | | | 2,567 | |

| Net cash provided by operating activities | | | 2,915 | | | | 15,174 | |

| Cash flows from investing activities | | | | | | |

| Payments related to acquisition, net of cash acquired | | | (6,226 | ) | | | — | |

| Purchases of property and equipment | | | (2,102 | ) | | | (748 | ) |

| Intangible assets expenditures | | | (52 | ) | | | (56 | ) |

| Payment for exclusive distribution agreement | | | (3,000 | ) | | | — | |

| Net cash used in investing activities | | | (11,380 | ) | | | (804 | ) |

| Cash flows from financing activities | | | | | | |

| Payments on note payable | | | — | | | | (1,500 | ) |

| Proceeds from exercise of common stock options | | | 197 | | | | 10 | |

| Proceeds from the issuance of common stock from the employee stock purchase plan | | | 1,032 | | | | 843 | |

| Payments for repurchases of common stock | | | (6,357 | ) | | | (26,562 | ) |

| Net cash used in financing activities | | | (5,128 | ) | | | (27,209 | ) |

| Net decrease in cash | | | (13,593 | ) | | | (12,839 | ) |

| Cash – beginning of period | | | 83,446 | | | | 94,367 | |

| Cash – end of period | | $ | 69,853 | | | $ | 81,528 | |

| | | | | | | |

| Supplemental cash flow disclosure | | | | | | |

| Cash paid for interest | | $ | 34 | | | $ | 828 | |

| Cash paid for taxes | | $ | 2,645 | | | $ | 892 | |

| Accrued excise tax on stock repurchases | | $ | — | | | $ | 210 | |

| Capital expenditures incurred but not yet paid | | $ | 147 | | | $ | 58 | |

The following table summarizes revenue by product line for the three and six months ended June 30, 2026 and 2025:

| | | | | | | | | | | | | |

| | | Three Months Ended | | Six Months Ended |

| | | June 30, | | June 30, |

| (In thousands) | | 2026 | | 2025 | | 2026 | | 2025 |

| Revenue | | | | | | | | | | | | |

| Lymphedema products | | $ | 73,630 | | | $ | 65,969 | | | $ | 135,851 | | | $ | 116,524 | |

| Airway clearance products | | | 12,068 | | | | 12,936 | | | | 25,114 | | | | 23,649 | |

| Total | | $ | 85,698 | | | $ | 78,905 | | | $ | 160,965 | | | $ | 140,173 | |

| | | | | | | | | | | | | |

| Percentage of total revenue | | | | | | | | | | | | |

| Lymphedema products | | | 86 | % | | | 84 | % | | | 84 | % | | | 83 | % |

| Airway clearance products | | | 14 | % | | | 16 | % | | | 16 | % | | | 17 | % |

| Total | | | 100 | % | | | 100 | % | | | 100 | % | | | 100 | % |

The following table contains a reconciliation of net income to Adjusted EBITDA for the three and six months ended June 30, 2026 and 2025, as well as the dollar and percentage change between the comparable periods:

| | | | | | | | | | | | | | | | | | | | | | | | | |

| Tactile Systems Technology, Inc. |

| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA |

| (Unaudited) |

| | | | | | | | | | | | | | | | | | | | | | | | | |

| | | Three Months Ended | | Increase | | Six Months Ended | | Increase |

| | | June 30, | | (Decrease) | | June 30, | | (Decrease) |

| (Dollars in thousands) | | 2026 | | 2025 | | $ | | % | | 2026 | | 2025 | | $ | | % |

| Net income | | $ | 7,785 | | | $ | 3,217 | | | $ | 4,568 | | | 142 | | % | | $ | 6,022 | | | $ | 243 | | | $ | 5,779 | | | N.M. | % |

| Interest (income) expense, net | | | (542 | ) | | | (440 | ) | | | (102 | ) | | 23 | | % | | | (1,180 | ) | | | (911 | ) | | | (269 | ) | | 30 | | % |

| Income tax (benefit) expense | | | (417 | ) | | | 1,307 | | | | (1,724 | ) | | (132 | ) | % | | | 450 | | | | 210 | | | | 240 | | | 114 | | % |

| Depreciation and amortization | | | 1,811 | | | | 1,659 | | | | 152 | | | 9 | | % | | | 3,450 | | | | 3,385 | | | | 65 | | | 2 | | % |

| Stock-based compensation | | | 2,260 | | | | 1,939 | | | | 321 | | | 17 | | % | | | 4,040 | | | | 4,005 | | | | 35 | | | 1 | | % |

| Acquisition & integration costs | | | 156 | | | | — | | | | 156 | | | — | | % | | | 973 | | | | — | | | | 973 | | | — | | % |

| Litigation-related costs | | | — | | | | — | | | | — | | | — | | % | | | 1,000 | | | | — | | | | 1,000 | | | — | | % |

| Executive transition costs | | | 360 | | | | — | | | | 360 | | | — | | % | | | 360 | | | | 491 | | | | (131 | ) | | (27 | ) | % |

| Adjusted EBITDA | | $ | 11,413 | | | $ | 7,682 | | | $ | 3,731 | | | 49 | | % | | $ | 15,115 | | | $ | 7,423 | | | $ | 7,692 | | | 104 | | % |

“N.M.” Not Meaningful

The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2025:

| | | | |

| Tactile Systems Technology, Inc. |

| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA |

| (Unaudited) |

| | | | |

| | | Year Ended |

| (Dollars in thousands) | | December 31, 2025 |

| Net income | | $ | 19,086 | |

| Interest (income) expense, net | | | (2,059 | ) |

| Income tax expense | | | 12,253 | |

| Depreciation and amortization | | | 6,644 | |

| Stock-based compensation | | | 8,357 | |

| Executive transition costs | | | 491 | |

| Adjusted EBITDA | | $ | 44,772 | |

The following table contains a reconciliation of GAAP net income guidance range to the Adjusted EBITDA guidance range for the twelve months ending December 31, 2026:

| | | | | | | |

| Tactile Systems Technology, Inc. |

| Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance |

| (Unaudited) |

| | | | | | | |

| | | Year Ended |

| | | December 31, 2026 |

| (Dollars in thousands) | | Low | | High |

| Net income | | $ | 23,230 | | | $ | 24,670 | |

| Interest (income) expense, net | | | (2,380 | ) | | | (2,380 | ) |

| Income tax expense | | | 9,420 | | | | 9,980 | |

| Depreciation and amortization | | | 7,510 | | | | 7,510 | |

| Stock-based compensation | | | 8,550 | | | | 8,550 | |

| Acquisition & integration costs | | | 1,310 | | | | 1,310 | |

| Executive transition costs | | | 360 | | | | 360 | |

| Litigation-related costs | | | 1,000 | | | | 1,000 | |

| Adjusted EBITDA | | $ | 49,000 | | | $ | 51,000 | |

Investor Inquiries: Sam Bentzinger Gilmartin Group [email protected]

Primary Logo

Source: Tactile Systems Technology, Inc.

Prompts

Tactile Systems Technology, Inc. (ticker TCMD), listed in United States.

ETFs Holding Tactile Systems Technology, Inc.

ETF Weight in ETF Shares Market value As of
MYLD 0.98% 11,752 $ 331.054K Jul 31, 2026
VAMO 0.93% 35,692 $ 1.005M Jul 31, 2026
LITL 0.61% 1,336 $ 34.803K Nov 17, 2026
NANC 0.60% 61,327 $ 1.617M Nov 17, 2026
DSMC 0.54% 23,393 $ 696.644K Jun 30, 2026
FSCC 0.43% 68,668 $ 1.578M Aug 31, 2026
AFSM 0.30% 16,613 $ 438.085K Nov 16, 2026
SQLV 0.27% 2,633 $ 78.411K Jun 30, 2026
SEIS 0.17% 32,489 $ 967.522K Jun 30, 2026
VFMF 0.14% 60,921 $ 1.4M Aug 31, 2026
BSVO 0.14% 133,087 $ 3.47M Nov 18, 2026
VFQY 0.12% 27,294 $ 627.216K Aug 31, 2026
VFMO 0.07% 62,386 $ 1.434M Aug 31, 2026
FESM 0.06% 121,214 $ 3.61M Jun 30, 2026
PSC 0.05% 41,404 $ 1.233M Jun 30, 2026
AVSC 0.04% 51,255 $ 1.352M Nov 16, 2026
RESM 0.03% 37 $ 1,101.86 Jun 30, 2026
DFAT 0.03% 321,932 $ 8.634M Nov 12, 2026
DFSV 0.02% 249,420 $ 6.689M Nov 12, 2026
DFAS 0.01% 168,177 $ 4.511M Nov 12, 2026
DXUV 0.00% 10,576 $ 283.648K Nov 12, 2026
DFAC 0.00% 92,620 $ 2.484M Nov 12, 2026
MSSM 0.00% 819 $ 18.821K Aug 31, 2026
DCOR 0.00% 36,720 $ 984.83K Nov 12, 2026
DFUS 0.00% 9,144 $ 245.242K Nov 12, 2026
DFAU 0.00% 4,772 $ 127.985K Nov 12, 2026
EBI 0.00% 31 $ 712.38 Aug 31, 2026
AVUS 0.00% 11,108 $ 292.918K Nov 16, 2026
AVUV 0.00% 56,205 $ 1.482M Nov 16, 2026
AVSU 0.00% 34 $ 896.58 Nov 16, 2026